Biomarkers for response to neoadjuvant chemoradiation for rectal cancer.
about
Immunological Landscape and Clinical Management of Rectal CancerNeoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancerGenotypic characteristics of resistant tumors to pre-operative ionizing radiation in rectal cancerP21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancerPredictive and prognostic molecular markers for cancer medicineIdentification of molecular characteristics induced by radiotherapy in rectal cancer based on microarray data.Role of tumor size in the pre-operative management of rectal cancer patients.Allelotyping identification of genomic alterations in rectal chromosomally unstable tumors without preoperative treatment.Neo-adjuvant chemo-radiation of rectal cancer with volumetric modulated arc therapy: summary of technical and dosimetric features and early clinical experience.Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer.Laboratory blood data have a significant impact on tumor response and outcome in preoperative chemoradiotherapy for advanced rectal cancer.Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer.Relationship of EMAST and microsatellite instability among patients with rectal cancer.Mechanistic insight into the ability of American ginseng to suppress colon cancer associated with colitis.The role of capecitabine in locally advanced rectal cancer treatment: an update.Multiplexed protein signal pathway mapping identifies patients with rectal cancer that responds to neoadjuvant treatment.Insulin-like growth factor receptor-1 overexpression is associated with poor response of rectal cancers to radiotherapy.Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer.Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsetsChromosomal copy number alterations are associated with tumor response to chemoradiation in locally advanced rectal cancerElevated platelet count as predictor of recurrence in rectal cancer patients undergoing preoperative chemoradiotherapy followed by surgery.Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatmentYKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional studyIdentification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancerClinical predictive circulating peptides in rectal cancer patients treated with neoadjuvant chemoradiotherapy.Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study.Predicting tumor response after preoperative chemoradiation using clinical parameters in rectal cancer.Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy.Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapyA prospective study on histone γ-H2AX and 53BP1 foci expression in rectal carcinoma patients: correlation with radiation therapy-induced outcomeThe molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies.Predictive value of APAF-1 and COX-2 expression in pathologic complete response to neoadjuvant chemoradiotherapy for patients with locally advanced rectal adenocarcinoma.Intratumoral Heterogeneity of MicroRNA Expression in Rectal Cancer.Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort studyResponse to chemoradiotherapy and lymph node involvement in locally advanced rectal cancerClinical parameters predicting pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer.A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patientsCircadian gene expression predicts patient response to neoadjuvant chemoradiation therapy for rectal cancer.Low expression of chloride channel accessory 1 predicts a poor prognosis in colorectal cancer.Treatment of locally advanced rectal cancer: controversies and questions.
P2860
Q26768531-EF7D8950-1FB3-46A0-A0A8-9A821868DC73Q27003878-D8BB1413-7A52-4419-8AC3-C7CD775C7AA5Q27007505-275C17AB-0C8B-495C-9BFB-D0A3B5F4029EQ27852992-4227CCEF-B03D-44F5-93E7-F0B5695293E1Q28743108-7EC47851-D6A3-4B5E-B383-4ECBE9D9D6E7Q33597819-820FFC29-4673-4D3A-AE59-55711A0A2A42Q33605399-A014123C-7D94-412E-B23A-0E7C1715699DQ33721457-FBC9AF1D-E0B7-4E38-B27D-E0A1609C67B0Q33729118-AEE3D802-04FC-4C83-A664-A02062E552A0Q33816412-81FC4AA0-9CD4-40C1-A5D1-5AF3702B8060Q33834316-DBD4D0D5-00A4-40A1-A5D2-ED555EC98E02Q33952083-D794B9D6-F63A-44A4-9931-36E79E8706F1Q34146223-8C4D22C9-0261-4207-B6F8-F7AC3F06E4A9Q34180271-26A09059-B166-424F-8D54-5BCC8A712520Q34276823-47BFC8C1-7BE4-42F1-B5C7-5943F836D7CFQ34289736-3767DB8C-C4F6-4B3B-B9D8-F605ED07E66BQ34552155-8BF34BA5-D396-4096-929C-F0CF919E3036Q35061159-E9DE79E5-7645-4F07-9779-F25A87CCAB31Q35083126-5F7DC160-680A-4599-8740-0CBD3BE0EA69Q35100017-AE68A5AB-B004-4E8B-A248-1AAEC22074DCQ35110652-0AD5DEB5-27C5-4EE3-B32C-434B9449021BQ35183525-695CA510-7451-419D-AC44-E755921BBB0DQ35433475-C1649CEF-A5BC-4777-A134-E3B1E6EDEA61Q35460703-C2D16B8E-7E81-421A-BB78-ED301E1D3875Q35529674-110DDC7D-62D3-467C-B4AE-B3614768EA77Q35607847-F2530A0F-F441-427D-B2FE-2E74E13C4840Q35638806-86F39444-23E2-46BB-A5DE-0B7BC50BA40EQ35661951-DB7CE6A6-F7A0-4BCC-86CF-F67BA4C07F32Q35814400-355BC48C-B432-4C55-92CA-44FD7C0410F4Q35833829-58884A20-4D43-46CF-9418-0FA4E1F6D200Q35859128-2D7F509F-AE45-4120-BAF2-241C58F4416AQ36011044-BF747111-32AF-48F0-A233-3119B737E6C9Q36040119-24ADF23A-F5E7-4426-8705-AB31E49B3073Q36085189-EFE6D246-6F88-42C6-B363-A1A2945A7061Q36091170-ED4ABB04-1BBA-4C3D-9ED0-1BE96C3D6311Q36121224-F8FF51BA-04D2-457E-9DCB-2C55675EBF83Q36211293-B2C499F0-EF6F-49DA-88F4-4AD5FD9745E2Q36261585-0D668647-5EA2-458A-AA4E-4BBE18327F7FQ36302699-34DB5E44-491F-4EAB-BAF9-8FFB37E08EDBQ36351882-750BE882-4485-4CB9-8645-59AD8C7D4F6B
P2860
Biomarkers for response to neoadjuvant chemoradiation for rectal cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biomarkers for response to neoadjuvant chemoradiation for rectal cancer.
@en
Biomarkers for response to neoadjuvant chemoradiation for rectal cancer.
@nl
type
label
Biomarkers for response to neoadjuvant chemoradiation for rectal cancer.
@en
Biomarkers for response to neoadjuvant chemoradiation for rectal cancer.
@nl
prefLabel
Biomarkers for response to neoadjuvant chemoradiation for rectal cancer.
@en
Biomarkers for response to neoadjuvant chemoradiation for rectal cancer.
@nl
P2093
P1476
Biomarkers for response to neoadjuvant chemoradiation for rectal cancer.
@en
P2093
Howard L McLeod
Jeffrey G Kuremsky
Joel E Tepper
P304
P356
10.1016/J.IJROBP.2009.03.003
P407
P577
2009-07-01T00:00:00Z